3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Small Cell Lung Carcinoma
2
Lung Neoplasms
1
Carcinoma, Small Cell
1
Interventions
Etoposide
34
Carboplatin
31
Topotecan
24
Cisplatin
21
atezolizumab
11
PM 01183
8
durvalumab
7
Irinotecan
7
amrubicin
5
PE regimen
4
AMG 757
4
rovalpituzumab tesirine
3
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Dexamethasone
3
tremelimumab
2
tislelizumab
2
etoposide phosphate
2
apatinib
2
Vitamin E
2
Tiragolumab
2
Specimen Handling
2
Radiosurgery
2
RRx-001
2
Paclitaxel
2
Memantine
2
Injections
2
EC regimen
2
trilaciclib
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Small Cell Lung Carcinoma
×
RRx-001
×
Clear all
NCT05566041
2024-10-31
REPLATINUM
EpicentRx, Inc.
Phase 3
Active not recruiting
292 enrolled
NCT03699956
2024-03-26
REPLATINUM
EpicentRx, Inc.
Phase 3
Terminated
18 enrolled